UK biosolutions a £1.46 billion frontier industry tackling climate change and regional security, BIA report identifies
London, UK, 20 April 2026 – The UK’s biosolutions sector has established itself as a billion-pound frontier industry, with companies raising £1.46 billion in equity investment since 2018, helping to insulate the UK from global resource shocks, according to new analysis from BIA BioSolutions.
The data from the Unlocking investment in UK biosolutions report shows biosolutions – technology that uses biological processes to transform global industries, including agriculture, chemicals, materials and fuels – has attracted significant international capital and now stands ready to scale again as market conditions improve. By replacing fossil-based, import‑dependent supply chains with domestic, biology‑based production, biosolutions are a critical security asset, providing a layer of economic resilience and national capability.
Drawing on in-house analysis of 155 innovative UK biosolutions companies, the report highlights the scale, maturity and global appeal of a sector built on the UK’s leadership in engineering biology.
A billion-pound frontier industry
Since 2018, UK biosolutions companies have raised £1.46 billion in equity finance, firmly establishing biosolutions as a major industrial opportunity alongside other UK frontier technologies and an asset for protecting the UK economy against external shocks. This scale reflects years of sustained company formation, investment and policy support that helped the sector accelerate sharply up to 2022. It is also indicative of increased market pull, as wider industries are increasingly seeking secure, low‑carbon and domestically anchored alternatives to imported inputs to help insulate their supply chains from uncertainty.
A globally competitive proposition
The UK has cemented its position as a leading destination for biosolutions investment, with UK companies attracting a predominantly international investor base. Between 2018 and 2025, over 60.6% of investors were based outside the UK, led by the US and Europe; a clear vote of confidence in the UK’s scientific excellence, regulatory environment and entrepreneurial quality.
Growth paused, but fundamentals remain strong
While the long-term trend shows rapid growth, the analysis also captures a clear arresting of momentum after 2022. Annual investment dipped in 2023 and 2024 before recovering to £259 million in 2025, reflecting broader macroeconomic conditions rather than any weakening of the sector’s underlying fundamentals. The consistency of deal activity, continued later-stage investment and growing international participation suggest there is significant innovation and company growth waiting to be unleashed as soon as global capital markets reopen.
Unlocking the next phase of growth
As the UK biosolutions sector enters its next phase, BIA highlights the critical role of enabling regulation, patient scale-up capital and accessible infrastructure in ensuring that future investment flows to the UK rather than overseas. Public funding, particularly through Innovate UK, continues to play a central role in de-risking early innovation and supporting the pipeline that feeds later-stage growth.
With the right regulatory frameworks and scale-up capacity in place, the UK is well positioned to turn today’s paused momentum into the next wave of industrial growth – cementing biosolutions as a cornerstone of a resilient, sustainable UK economy.
Jane Wall, Managing Director at BIA, said:
“As global supply chains face increasing pressure and resource volatility, biotechnology is becoming central to strengthening our strategic autonomy and ability to diversify. By driving demand for bio-based products and creating strong regional and global collaborations of like-minded nations, we can protect both our economies and the planet.
“At BIA, our mission is to ensure the UK remains the global destination for this 'biorevolution.' We aren't just observing these trends; we are on the ground, championing the policy shifts and patient capital reforms needed to secure the UK’s strategic autonomy and global leadership. The future is bio-engineered, and through BIA BioSolutions, we are providing the platform to scale it.”
